Published 1 year ago

Pfizer's hemophilia B gene therapy succeeds in late-stage study

Summary by Ground News

Pfizer's investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial. The trial involved adults males with a moderately severe to severe form of the disease. Pfizer plans to disclose additional key data from the study at a scientific conference in early 2023.

0 Articles

All

Left

Center

Right

The Hindu

Pfizer’s haemophilia B gene therapy succeeds in late-stage study

Haemophilia B is an inherited disorder hampers the body's ability to make a blood-clotting protein called factor IX.

1 year ago·India

Read Full Article

Channel News Asia

Pfizer's hemophilia B gene therapy succeeds in late-stage study

US drugmaker Pfizer said on Thursday (Dec 29) its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduc

1 year ago·Singapore

Read Full Article

Bloomberg

Pfizer Hemophilia Gene Therapy Hits Goal in Final-Stage Study

Pfizer Inc.’s gene therapy for a hemophilia B hit its main goal in a final-stage trial, moving closer to becoming a competitor to a similar one-time treatment that costs $3.5 million.

1 year ago·United States

Read Full Article

WTVB

Pfizer’s hemophilia B gene therapy succeeds in late-stage study

(Reuters) - U.S. drugmaker Pfizer Inc said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduce the bleeding rate in patients with moderately severe to severe forms of hemophilia B. The disorder hampers the body's ability t…

1 year ago

Read Full Article